2015 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
December 14, 2015

Oncobiologics Expands Its Board Of Directors With The Appointment Of Three New Independent Membersmore >

October 05, 2015

ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial more >

September 29, 2015

Oncobiologics Secures Financing from Sabby Management, LLC more >

September 16, 2015

Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer more >

July 27, 2015

Oncobiologics Secures $31 Million Financing more >

July 02, 2015

Noted Immunology Expert Joins Oncobiologics as Chief Medical Officer more >

May 04, 2015

Oncobiologics opens commercial launch manufacturing facility more >

April 15, 2015

Oncobiologics announces completion of clinical dosing for bevacizumab (Avastin® biosimilar) candidate more >

February 12, 2015

ONS-3010 (Humira®/adalimumab biosimilar) meets primary endpoints in first clinical study more >